AU2001278779A1 - Aqueous suspension preparations - Google Patents

Aqueous suspension preparations

Info

Publication number
AU2001278779A1
AU2001278779A1 AU2001278779A AU7877901A AU2001278779A1 AU 2001278779 A1 AU2001278779 A1 AU 2001278779A1 AU 2001278779 A AU2001278779 A AU 2001278779A AU 7877901 A AU7877901 A AU 7877901A AU 2001278779 A1 AU2001278779 A1 AU 2001278779A1
Authority
AU
Australia
Prior art keywords
aqueous suspension
suspension preparations
preparations
aqueous
suspension
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001278779A
Inventor
Shirou Sawa
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Senju Pharmaceutical Co Ltd
Original Assignee
Senju Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Senju Pharmaceutical Co Ltd filed Critical Senju Pharmaceutical Co Ltd
Publication of AU2001278779A1 publication Critical patent/AU2001278779A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0046—Ear
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
    • A61K31/198—Alpha-aminoacids, e.g. alanine, edetic acids [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
AU2001278779A 2000-08-25 2001-08-20 Aqueous suspension preparations Abandoned AU2001278779A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2000-255000 2000-08-25
JP2000255000 2000-08-25
PCT/JP2001/007128 WO2002015878A1 (en) 2000-08-25 2001-08-20 Aqueous suspension preparations

Publications (1)

Publication Number Publication Date
AU2001278779A1 true AU2001278779A1 (en) 2002-03-04

Family

ID=18743862

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001278779A Abandoned AU2001278779A1 (en) 2000-08-25 2001-08-20 Aqueous suspension preparations

Country Status (6)

Country Link
US (2) US20030195179A1 (en)
EP (1) EP1312356B1 (en)
JP (2) JP5000835B2 (en)
AU (1) AU2001278779A1 (en)
ES (1) ES2396598T3 (en)
WO (1) WO2002015878A1 (en)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI320713B (en) 2001-06-01 2010-02-21 Neochemir Inc
JP2004189731A (en) * 2002-11-26 2004-07-08 Taisho Pharmaceut Co Ltd Nasal drop
EP1663144A1 (en) * 2003-09-23 2006-06-07 Alcon, Inc. Triamcinolone acetonide and anecortave acetate formulations for injection
US20080306039A1 (en) * 2003-12-02 2008-12-11 Keiichi Matsuhisa Loteprednol Etabonate Aqueous Suspension
BRPI0506983A (en) * 2004-01-20 2007-07-03 Allergan Inc localized eye therapy compositions, preferably comprising triamcinolone acetonide and hyaluronic acid
KR20050104152A (en) * 2004-04-28 2005-11-02 최승호 Enhancing systems for poorly absorptive drugs
EP1744731A1 (en) * 2004-04-28 2007-01-24 Procarrier, Inc. Oral formulation for delivery of poorly absorbed drugs
WO2006030851A1 (en) * 2004-09-15 2006-03-23 Santen Pharmaceutical Co., Ltd. Pirenoxine suspension type eye lotion
JP4766653B2 (en) * 2005-01-28 2011-09-07 株式会社林原生物化学研究所 Ophthalmic pharmaceutical composition
WO2006129386A1 (en) 2005-06-03 2006-12-07 Medrx Co., Ltd. Enteric medicinal composition for oral use
EP1911447B1 (en) 2005-07-11 2009-12-23 Senju Pharmaceutical Co., Ltd. Eye drop preparation comprising xanthan gum and terpenoid
US8653145B2 (en) * 2005-09-22 2014-02-18 Eaton Scientific Systems, Ltd. Method for alleviating climacteric symptoms
BRPI0620080A2 (en) * 2005-12-19 2011-11-01 Comentis Inc topical mecamylamine formulations for ocular administration and uses thereof
CN101848715A (en) * 2007-08-09 2010-09-29 千寿制药株式会社 Two-component eye drops containing pirenoxine
DK2262506T3 (en) * 2008-03-11 2014-06-10 Alcon Res Ltd HIGHLY FLOCCULATED TRIAMCINOLONACETONIDE SUSPENSIONS WITH LOW VISCOSITY FOR INTRAVITREAL INJECTION
CN102026665A (en) * 2008-05-19 2011-04-20 爱尔康研究有限公司 Pharmaceutical compositions having carboxyvinyl polymer and povidone polymer
US8283165B2 (en) * 2008-09-12 2012-10-09 Genvault Corporation Matrices and media for storage and stabilization of biomolecules
WO2010069519A1 (en) * 2008-12-18 2010-06-24 Merz Pharma Gmbh & Co. Kgaa Topical compositions comprising at least one active ingredient poorly soluble in water and biopolymers such as hyaluronic acid with a pka-value between 5-7
ES2391721T3 (en) 2010-03-01 2012-11-29 Laboratorios Salvat, S.A. Transparent aqueous solutions of fluocinolone acetonide for the treatment of ear swelling
BR112013024034A2 (en) * 2011-03-24 2016-12-13 Otsuka Pharma Co Ltd pharmaceutical composition for treating oral cavity disease comprising rebamipide
MX2013012307A (en) * 2011-04-22 2014-01-31 Alcon Res Ltd Ophthalmic composition with a viscosity enhancement system having two different viscosity enhancing agents.
AR090775A1 (en) 2012-04-23 2014-12-03 Otsuka Pharma Co Ltd INJECTABLE PREPARATION
WO2014102802A1 (en) * 2012-12-30 2014-07-03 Hadasit Medical Research Services And Development Ltd. Alginate compositions and uses thereof
EP2948130B1 (en) * 2013-01-24 2019-03-13 Rigel Pharmaceuticals, Inc. Composition for ophthalmic administration
BR112016010358B1 (en) 2013-11-08 2022-07-26 Activus Pharma Co., Ltd. AQUEOUS SUSPENSION FORMULATION INCLUDING MACROLIDE ANTIBIOTIC NANOPARTICLES
US20180193462A1 (en) * 2014-01-01 2018-07-12 Real Time Imaging Technologies, Llc Improved local anesthetic solution for dental and/or contrast media use
US9421199B2 (en) 2014-06-24 2016-08-23 Sydnexis, Inc. Ophthalmic composition
US11382909B2 (en) 2014-09-05 2022-07-12 Sydnexis, Inc. Ophthalmic composition
WO2016115117A1 (en) 2015-01-12 2016-07-21 Real Time Imaging Technologies, Llc Low-dose x-ray imaging system
CN107847432A (en) 2015-05-29 2018-03-27 西德奈克西斯公司 D2The stabilized pharmaceutical preparations of O
EP3927312B1 (en) 2019-02-22 2023-09-13 Catalent U.K. Swindon Zydis Limited Minimizing agglomeration, aeration, and preserving the coating of pharmaceutical compositions comprising ibuprofen
AR118419A1 (en) 2019-02-22 2021-10-06 Catalent Uk Swindon Zydis Ltd MINIMIZATION OF AGGLOMERATION OF DRUG PARTICLE COATING MATERIAL DURING STORAGE TO STABILIZE THE DISINTEGRATION TIMES OF PHARMACEUTICAL PRODUCTS
CN115869254A (en) * 2021-09-29 2023-03-31 成都瑞沐生物医药科技有限公司 Antibiotic eye preparation and preparation method and application thereof

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2731387A (en) * 1951-05-15 1956-01-17 Schenley Ind Inc Aqueous suspension of procaine penicillin
US4194090A (en) * 1976-11-27 1980-03-18 Nippon Electric Co., Ltd. Decentralized-control type electronic switching system
US4914090A (en) * 1985-11-01 1990-04-03 Schering Corporation Ophthalmic compositions
US5192535A (en) * 1988-02-08 1993-03-09 Insite Vision Incorporated Ophthalmic suspensions
JPH0737386B2 (en) * 1988-10-12 1995-04-26 参天製薬株式会社 Suspension type pyrenoxine eye drops
US5527545A (en) * 1989-09-18 1996-06-18 Recordati S.A. Chemical And Pharmaceutical Company Liquid-suspension controlled-release pharmaceutical composition
JPH059125A (en) * 1991-06-28 1993-01-19 Nippon Saafuakutanto Kogyo Kk Aqueous dispersion of royal jelly
US5318780A (en) * 1991-10-30 1994-06-07 Mediventures Inc. Medical uses of in situ formed gels
JPH0616556A (en) * 1992-07-02 1994-01-25 Yoshitomi Pharmaceut Ind Ltd Slightly soluble medicine-containing preparation
ES2079994B1 (en) * 1992-10-07 1996-08-01 Cusi Lab PHARMACEUTICAL FORMULATION BASED ON POLYMIXINE-TRIMETOPRIM AND AN ANTI-INFLAMMATORY AGENT FOR ITS TOPICAL OPHTHALMIC AND ETHICAL USE.
CA2166722A1 (en) * 1994-05-06 1995-11-16 Manoj L. Maniar Use of vitamin e tocopheryl derivatives in ophthalmic compositions
FR2720631B1 (en) * 1994-06-03 1996-07-12 Rhone Poulenc Rorer Sa Preparation process and beads obtained containing an active ingredient having an undefined melting point.
US5455049A (en) * 1995-01-04 1995-10-03 Ascent Pharmaceuticals, Inc. Terfenadine oral powder
US5696101A (en) * 1996-04-16 1997-12-09 Eastman Chemical Company Oxidized cellulose and vitamin E blend for topical hemostatic applications
US5763449A (en) * 1996-08-07 1998-06-09 Ascent Pediatrics, Inc. Pleasant-tasting aqueous liquid composition of a bitter-tasting drug
KR20010012188A (en) 1997-05-14 2001-02-15 요시다 쇼지 Aqueous suspension preparations with excellent redispersibility
JPH1121229A (en) * 1997-06-30 1999-01-26 Kyoto Yakuhin Kogyo Kk Antifungal external preparation and its production
GB9718568D0 (en) * 1997-09-03 1997-11-05 Chauvin Pharmaceuticals Limite Compositions
EP1020194A4 (en) * 1997-10-01 2003-05-21 Wakamoto Pharma Co Ltd O/w emulsion compositions
US6111757A (en) 1998-01-16 2000-08-29 International Business Machines Corp. SIMM/DIMM memory module
CA2318642A1 (en) * 1998-01-22 1999-07-29 Santen Pharmaceutical Co., Ltd. Fluorometholone ophthalmic suspension
PL194914B1 (en) * 1998-04-02 2007-07-31 Novartis Ag Method for stabilizing pharmaceutical compositions by special use of an antioxidant
CA2383971A1 (en) * 1999-09-06 2001-03-15 Hiroaki Naka Prophylactic and therapeutic medicaments for ophthalmic diseases

Also Published As

Publication number Publication date
JP5000835B2 (en) 2012-08-15
WO2002015878A1 (en) 2002-02-28
JPWO2002015878A1 (en) 2004-01-15
ES2396598T3 (en) 2013-02-22
EP1312356A1 (en) 2003-05-21
EP1312356B1 (en) 2012-10-17
US20090253807A1 (en) 2009-10-08
JP2012121912A (en) 2012-06-28
US8658703B2 (en) 2014-02-25
EP1312356A4 (en) 2007-11-21
US20030195179A1 (en) 2003-10-16

Similar Documents

Publication Publication Date Title
AU2001278779A1 (en) Aqueous suspension preparations
AU2001294192A1 (en) Solid preparations
AU2001232799A1 (en) Protein c derivatives
AU2001280099A1 (en) 4-acylaminopyrazole derivatives
AU2001249147A1 (en) Axle suspension connection
AU2001230584A1 (en) 1h-imidazopyridine derivatives
AU2001230537A1 (en) Pyridoxazine derivatives
AU2002217032A1 (en) Pigment preparations
AU1548001A (en) Ophthalmic aqueous preparation
AU2001281802A1 (en) 6-phenylpyrrolopyrimidinedione derivatives
AU2001259472A1 (en) Aqueous adhesive formulations
AU2001278790A1 (en) 1h-imidazopyridine derivatives
AU2002212301A1 (en) Diazacycloalkanedione derivatives
AU2002212516A1 (en) Suspension system
AU2001242479A1 (en) Proliposomal encapsulated preparations
AU2002212959A1 (en) Cycloalkylfluorosulfonamide derivatives
AU2001226338A1 (en) Dermatological suspensions (micro-matrix)
AU2002215212A1 (en) 1-methylcarbapenem derivatives
AU2001254661A1 (en) Aminosulfonylbiphenyl derivatives
AU2001230565A1 (en) Perfluoroisopropylbenzene derivatives
AU4165999A (en) Pesticide preparations in the form of aqueous suspension
AU2001242772A1 (en) 3-substituted-4-pyrimidone derivatives
AU2001288102A1 (en) Solid preparations
AU2001282521A1 (en) OCT preparations
AU2001272427A1 (en) Solid preparations